Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown

Blood (2024) 144 (Supplement 1): 987.

https://doi.org/10.1182/blood-2024-198452

Published: 2024

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Emmanuel Bachy, Peter Trask, Franck Morschhauser, Paolo Corradini, Shang-Ju Wu, Nancy L. Bartlett, Estefania Mulvihill, Fabiola Bene Tchaleu, Linda Lundberg, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2024-194337

Published: 2024

Journal Articles

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Marina Bacac, Johannes Sam, Won Seog Kim, Gareth P. Gregory, Matthew Ku, Sylvia Herter, Christian Klein, Pablo Umana, Stephen Simko, Victor Orellana-Noia, Linda Lundberg, Alessia Bottos

Blood (2024) 144 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2024-200753

Published: 2024

Journal Articles

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang

Blood (2024) 144 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2024-198424

Published: 2024

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Matthew Matasar, Toby A. Eyre, Eva Gine, Audrey Filézac De L'Étang, Ben Byrne, Linda Lundberg, Alejandra Padovani, Christophe Boetsch, Alessia Bottos, Naseer Qayum

Blood (2023) 142 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2023-173946

Published: 2023

Journal Articles

New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Nicolas Frey, Jean-Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David John Carlile, James Relf, Michael C. Wei, Antonia Kwan, Susan Grange

Blood (2023) 142 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2023-177679

Published: 2023

Journal Articles

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Blood (2022) 140 (Supplement 1): 1062–1064.

https://doi.org/10.1182/blood-2022-157554

Published: 2022

Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 178–180.

https://doi.org/10.1182/blood-2022-157777

Published: 2022

Journal Articles

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2021-146845

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Nassim Djebli, Peter N Morcos, Félix Jaminion, Elena Guerini, Nicole A Kratochwil, Nicole Justies, Eginhard Schick, Antonia Kwan, Kathryn Humphrey, Linda Lundberg, David Carlile

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136311

Published: 2020

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-136044

Published: 2020

NARROW

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only